Unlock instant, AI-driven research and patent intelligence for your innovation.

Beta-secretase enzyme compositions and methods

a technology of beta secretase and composition, applied in the field of beta secretase, can solve the problems of abnormal concentration of a peptide in amyloid plaques present in brains of people, and achieve the effect of maintaining or improving cognitive ability, reducing the amount of a deposition

Inactive Publication Date: 2005-07-28
ELAN PHARM INC
View PDF41 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0020] According to a further related aspect, the invention includes a method of screening for drugs effective in the treatment of Alzheimer's disease or other cerebrovascular amyloidosis characterized by Aβ deposition. According to this aspect of the invention, a mammalian subject characterized by overexpression of β-APP and/or deposition of Aβ is given a test compound selected for its ability to inhi

Problems solved by technology

It is not clear whether β-secretase enzyme levels and/or activity is inherently higher than normal in Alzheimer's patients; how

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Beta-secretase enzyme compositions and methods
  • Beta-secretase enzyme compositions and methods
  • Beta-secretase enzyme compositions and methods

Examples

Experimental program
Comparison scheme
Effect test

example 1

Isolation of Coding Sequences for Human β-Secretase

A. PCR Cloning

[0302] Poly A+ RNA from IMR human neuroblastoma cells was reverse transcribed using the Perkin-Elmer kit. Eight degenerate primer pools, each 8 fold degenerate, encoding the N and C terminal portions of the amino acid sequence obtained from the purified protein were designed (shown in Table 4; oligos 3407 through 3422)(SEQ ID NOS:3-21). PCR reactions were composed of cDNA from 10 ng of RNA, 1.5 mM MgCl2, 0.125 μl AmpliTaq® Gold, 160 μM each dNTP (plus 20 μM additional from the reverse transcriptase reaction), Perkin-Elmer TAQ buffer (from AmpliTaq® Gold kit, Perkin-Elmer, Foster City, Calif. ), in a 25 μl reaction volume. Each of oligonucleotide primers 3407 through 3414 was used in combination with each of oligos 3415 through 3422 for a total for 64 reactions. Reactions were run on the Perkin-Elmer 7700 Sequence Detection machine under the following conditions: 10 min at 95° C., 4 cycles of, 45° C. annealing for 15...

example 2

Screening of Human Fetal Brain cDNA Library

[0312] The Origene human fetal brain Rapid-Screen™ cDNA Library Panel is provided as a 96-well format array consisting of 5000 clones (plasmid DNA) per well from a human fetal brain library. Subplates are available for each well consisting of 96 wells of 50 clones each in E. coli. This is an oligo-dT primed library, size-selected and unidirectionally inserted into the vector pCMV-XL3.

[0313] 94 wells from the master plate were screened using PCR. The Reaction 1 Conditions described in Example 1, above, were followed, using only primers 3407 (SEQ ID NO:3) and 3416 (SEQ ID NO:12) with 30 ng of plasmid DNA from each well. Two pools showed the positive 70 bp band. The same primers and conditions were used to screen 1 μl E. coli from each well of one of the subplates. E. coli from the single positive well was then plated onto LB / amp plates and single colonies screened using the same PCR conditions. The positive clone, about 1 Kb in size, was la...

example 3

PCR Cloning Methods

[0314] 3′RACE was used in experiments carried out in support of the present invention to elucidate the polynucleotide encoding human β-secretase. Methods and conditions appropriate for replicating the experiments described herein and / or determining polynucleotide sequences encoding additional members of the novel family of aspartyl proteases described herein may be found, for example, in White, B. A., ed., PCR Cloning Protocols; Humana Press, Totowa, N.J., 1997, or Ausubel, supra, both of which are incorporated herein by reference.

RT-PCR

[0315] For reverse transcription polymerase chain reaction (RT-PCR), two partially degenerate primer sets used for RT-PCR amplification of a cDNA fragment encoding this peptide. Primer set 1 consisted of DNA's #3427-3434 (SEQ ID NOS:22-29 respectively), the sequences of which are shown in Table 5, below. Matrix RT-PCR using combinations of primers from this set with cDNA reverse transcribed from primary human neuronal cultures ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

Disclosed are various forms of an active, isolated β-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (β-APPwt and β-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate β-secretase. Inhibitors of β-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. application Ser. No. 09 / 723,722, filed Nov. 28, 2000 (incorporated by reference), which is a continuation of U.S. application Ser. No. 09 / 501,708, filed Feb. 10, 2000 (incorporated by reference), which is a continuation-in-part of U.S. application Ser. No. 09 / 471,669, filed Dec. 24, 1999, which claims the benefit under 35 U.S.C. 119(e) of U.S. application Ser. No. 60 / 119,571 (incorporated by reference), filed Feb. 10, 1999, and which also claims the benefit under 35 U.S.C. 119(e) of U.S. application Ser. No. 60 / 139,172 (incorporated by reference), filed Jun. 15, 1999. U.S. application Ser. No. 09 / 501,708 also claims the benefit under 35 U.S.C. 119(e) of U.S. application Ser. No. 60 / 119,571 filed Feb. 10, 1999, and U.S. application Ser. No. 60 / 139,172. The present application is also a continuation-in-part of U.S. application Ser. No. 09 / 471,669, filed Dec. 24, 1999, which also claims the benef...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/00C12N9/64H01Q1/36H01Q1/38H01Q3/44H01Q5/00H01Q9/04H01Q15/02
CPCA01K2217/075A61K38/00C12N9/6478H01Q1/364H01Q15/02H01Q3/44H01Q9/0407H01Q9/0442H01Q1/38
Inventor ANDERSON, JOHNBASI, GURIQBALDOAN, MINHFRIGON, NORMANDJOHN, VARGHESEPOWER, MICHAELSINHA, SUKANTOTATSUNO, GWENTUNG, JAYWANG, SHUWENMCCONLOGUE, LISA
Owner ELAN PHARM INC